Engineered immune cells take on childhood cancer
NCT ID NCT03294954
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a new approach for children with neuroblastoma that has come back or not responded to standard treatment. Researchers take the child's own natural killer T cells, add genes to help them recognize and attack neuroblastoma cells, and give them back along with a drug called Etanercept. The goal is to find a safe dose and see if the cells can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GINAKIT cells (genetically modified natural killer T cells) with or without Etanercept
What this could lead to
If successful, this could point toward a new treatment option for children with hard-to-treat neuroblastoma by using the body's own immune cells to attack the cancer.
What could go wrong
This is an early Phase 1 trial with only 70 participants, so it is too soon to know if it works. The modified cells may cause side effects or not shrink tumors, and combining them with Etanercept adds unknown risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••